Study Title and Description
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Key Questions Addressed
|2||Key Question 2. In adult women without preexisting breast cancer, what is the effectiveness and comparative effectiveness of medications to reduce risk for primary breast cancer on improvement in short- and long-term health outcomes, including invasive breast cancer, noninvasive breast cancer (including ductal carcinoma in situ), breast cancer mortality, all-cause mortality, and other beneficial outcomes (such as reduced fractures caused by certain medications and improved quality of life)? Key Question 2a. Does the effectiveness of risk-reducing medications vary by timing of initiation or duration of use? Key Question 2b. Does the effectiveness of risk-reducing medications persist beyond discontinuation of use?|
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
|4||Key Question 4. How do outcomes vary by population subgroups?|
Primary Publication Information
|Title||Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.|
|Author||Cuzick J., Forbes JF., Sestak I., Cawthorn S., Hamed H., Holli K., Howell A.|
|Country||Centre for Epidemiology, Mathematics, and Statistics, Cancer Research UK, Wolfson Institute of Preventive Medicine, Charterhouse Square, London EC1M 6BQ, UK. firstname.lastname@example.org|
Pubmed ID: 17312304
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.